drugset / Trial / NCT00843193

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193

Phase 2 Completed 198 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study

Timeline

Start
2008-12-09
Primary completion
2010-07-25
Completion
2010-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK679586 Monoclonal antibody 10 mg/kg Intravenous
Background Fluticasone propionate Other / unclassified 1000 ug

Indications